[{"id":"33c19810-9a20-4b78-b0f9-9d759996abd8","acronym":"","url":"https://clinicaltrials.gov/study/NCT02301130","created_at":"2021-01-18T10:52:39.063Z","updated_at":"2025-02-25T15:06:18.589Z","phase":"Phase 1","brief_title":"Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors","source_id_and_acronym":"NCT02301130","lead_sponsor":"Kyowa Kirin, Inc.","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Poteligeo (mogamulizumab-kpkc)"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 11/26/2014","start_date":" 11/26/2014","primary_txt":" Primary completion: 12/08/2017","primary_completion_date":" 12/08/2017","study_txt":" Completion: 03/05/2018","study_completion_date":" 03/05/2018","last_update_posted":"2024-04-25"},{"id":"b5d237d9-2e35-4f25-8d94-e3921b32c0ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT00888927","created_at":"2021-01-29T06:59:27.729Z","updated_at":"2024-07-02T16:35:07.654Z","phase":"Phase 1/2","brief_title":"Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma","source_id_and_acronym":"NCT00888927","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Poteligeo (mogamulizumab-kpkc)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 09/01/2012","primary_completion_date":" 09/01/2012","study_txt":" Completion: 09/01/2012","study_completion_date":" 09/01/2012","last_update_posted":"2024-04-25"},{"id":"98dc230c-608b-4b96-98ca-93699a4a09ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT05414500","created_at":"2022-06-10T12:58:47.286Z","updated_at":"2024-07-02T16:35:25.996Z","phase":"Phase 1","brief_title":"Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides","source_id_and_acronym":"NCT05414500","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin) • Poteligeo (mogamulizumab-kpkc)"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 05/01/2023","start_date":" 05/01/2023","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-12-18"},{"id":"71343729-1bac-4081-80f8-a294b7151b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT04185220","created_at":"2021-01-18T20:24:07.273Z","updated_at":"2024-07-02T16:35:58.235Z","phase":"Phase 1","brief_title":"Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome","source_id_and_acronym":"NCT04185220","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TNFRSF8 • IL15","pipe":"","alterations":" ","tags":["TNFRSF8 • IL15"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Poteligeo (mogamulizumab-kpkc) • rhIL-15"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 02/26/2020","start_date":" 02/26/2020","primary_txt":" Primary completion: 11/06/2020","primary_completion_date":" 11/06/2020","study_txt":" Completion: 05/18/2022","study_completion_date":" 05/18/2022","last_update_posted":"2023-01-04"},{"id":"7a02446f-0144-4139-9eb2-b2e58aec4a6b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02946671","created_at":"2021-01-18T14:28:00.760Z","updated_at":"2024-07-02T16:36:49.098Z","phase":"Phase 1","brief_title":"Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients","source_id_and_acronym":"NCT02946671","lead_sponsor":"Osaka University","biomarkers":" FOXP3","pipe":"","alterations":" ","tags":["FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Poteligeo (mogamulizumab-kpkc)"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2020","study_completion_date":" 03/01/2020","last_update_posted":"2020-03-06"},{"id":"76077b4b-8f34-46fa-80c6-ee0796071907","acronym":"","url":"https://clinicaltrials.gov/study/NCT02358473","created_at":"2021-01-18T11:13:33.105Z","updated_at":"2024-07-02T16:37:04.951Z","phase":"Phase 1","brief_title":"Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02358473","lead_sponsor":"Kyowa Kirin, Inc.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Poteligeo (mogamulizumab-kpkc)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2018-11-30"},{"id":"e6de9ac1-93ef-4478-a4b2-f0781d7a19e6","acronym":"","url":"https://clinicaltrials.gov/study/NCT01173887","created_at":"2021-01-18T04:40:58.159Z","updated_at":"2024-07-02T16:37:23.941Z","phase":"Phase 2","brief_title":"Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15","source_id_and_acronym":"NCT01173887","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" CCR4","pipe":"","alterations":" ","tags":["CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • doxorubicin hydrochloride • cyclophosphamide • Poteligeo (mogamulizumab-kpkc) • Cymerin (ranimustine) • vindesine"],"overall_status":"Completed","enrollment":" Enrollment 44","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 04/01/2012","primary_completion_date":" 04/01/2012","study_txt":" Completion: 04/01/2012","study_completion_date":" 04/01/2012","last_update_posted":"2017-03-30"},{"id":"9cadd003-64c3-4e91-a4a3-5445b9b25baa","acronym":"","url":"https://clinicaltrials.gov/study/NCT00920790","created_at":"2021-01-18T03:33:47.062Z","updated_at":"2024-07-02T16:37:23.967Z","phase":"Phase 2","brief_title":"Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma","source_id_and_acronym":"NCT00920790","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" CCR4","pipe":"","alterations":" ","tags":["CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Poteligeo (mogamulizumab-kpkc)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 07/01/2010","primary_completion_date":" 07/01/2010","study_txt":" Completion: 11/01/2010","study_completion_date":" 11/01/2010","last_update_posted":"2017-03-29"},{"id":"fafcb33f-53f7-418a-8132-c9f7ec4dba43","acronym":"","url":"https://clinicaltrials.gov/study/NCT01192984","created_at":"2021-01-18T04:46:25.810Z","updated_at":"2024-07-02T16:37:24.803Z","phase":"Phase 2","brief_title":"Study of KW-0761 in Subjects With CCR4-positive Peripheral T/NK-cell Lymphoma","source_id_and_acronym":"NCT01192984","lead_sponsor":"Kyowa Kirin Co., Ltd.","biomarkers":" CCR4","pipe":"","alterations":" ","tags":["CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Poteligeo (mogamulizumab-kpkc)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 09/01/2010","start_date":" 09/01/2010","primary_txt":" Primary completion: 05/01/2012","primary_completion_date":" 05/01/2012","study_txt":" Completion: 05/01/2012","study_completion_date":" 05/01/2012","last_update_posted":"2017-03-03"},{"id":"581bfd7c-0d1f-4d70-b389-31aab6e8dd83","acronym":"","url":"https://clinicaltrials.gov/study/NCT01611142","created_at":"2021-01-18T06:53:56.383Z","updated_at":"2024-07-02T16:37:31.359Z","phase":"Phase 2","brief_title":"Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)","source_id_and_acronym":"NCT01611142","lead_sponsor":"Kyowa Hakko Kirin Pharma, Inc.","biomarkers":" ALK • CCR4","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • CCR4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Poteligeo (mogamulizumab-kpkc)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2012","start_date":" 04/01/2012","primary_txt":" Primary completion: 05/01/2015","primary_completion_date":" 05/01/2015","study_txt":" Completion: 05/01/2015","study_completion_date":" 05/01/2015","last_update_posted":"2016-06-14"}]